<DOC>
	<DOCNO>NCT01764126</DOCNO>
	<brief_summary>This observer-blind , randomise , vaccine-controlled , vaccine trial determine safety immunogenicity pneumococcal protein vaccine . It use age step-down approach begin adult , toddler infant , data safety review stage step next age group . Adults toddler receive dose three-protein ( trivalent ) vaccine ( PcpA , PhtD , PlyD1 proteins ) 50µg . Infants start low dose ( 10 µg ) , medium dose ( 25µg ) high dose ( 50µg ) , safety review stage ascend next high dose . Infants also receive concomitant standard EPI childhood vaccine . Safety assess close monitoring begin day vaccination ( day 0 ) subsequent seven day , record solicit non-solicited adverse event . Immunogenicity assess specific antibody response three protein . The study aim recruit 280 study subject across age group .</brief_summary>
	<brief_title>Pneumococcal Protein Vaccine Safety Immunogenicity Trial</brief_title>
	<detailed_description>This Phase I , single-center , randomize , placebo-controlled , step-down observer-blind study assess safety immunogenicity single injection PPrV vaccine contain 50 µg protein ( PcpA , PhtD PlyD1 ) withadjuvant healthy adult toddler , 3 injection healthy infant ( follow Expanded Program Immunization [ EPI ] schedule ) 3 ascend dose level ( adjuvanted 10 , 25 , 50µg protein per dose level ; additional un-adjuvanted formulation 25 µg protein per dose level ) . Overall , 5 Cohorts . In Cohort I , adult receive 1 injection adjuvanted 50 µg PcpA , PhtD PlyD1 PPrV vaccine ( high dose ) placebo . In Cohort II , toddler receive 1 injection adjuvanted 50 µg PcpA , PhtD PlyD1 PPrV vaccine placebo . In Cohorts III , IV V , infant receive 3 injection one follow PPrV vaccine formulation : adjuvanted 10 µg PcpA , PhtD PlyD1 ( low dose ) , adjuvanted 25 µg PcpA , PhtD PlyD1 ( middle dose ) , unadjuvanted 25 µg PcpA , PhtD PlyD1 ( middle dose un-adjuvanted ) , adjuvanted 50 µg PcpA , PhtD PlyD1 ( high dose ) placebo , accord EPI schedule ( 6 week , 10 week 14 week ) , well concomitant applicable standard care childhood vaccine ( Quinvaxem® [ DTwP-HepB-Hib ] vaccine , Bacillus Calmette-Guérin vaccine ( BCG ) ( receive birth ) , oral poliomyelitis vaccine [ OPV ] ) . As safety precaution , trial use step-down approach enrollment : adult , 1 vaccination acceptable review safety data collect Day 7 injection , follow enrollment toddler , 1 vaccination acceptable review safety data collect Day 7 injection , enrollment infant ( 3 injection , EPI schedule ) . For infant , step-wise dose ascension conditional upon acceptable safety review , conduct completion third vaccination EPI series dose level , use safety data collect Day 7 vaccination . An Independent Data Monitoring Committee ( IDMC ) establish safety oversight study , formal IDMC charter develop . For safety review , blind safety data provide Sponsor 's Safety Management Team ( SMT ) . The review perform SMT presentation finding , per standard early safety review process , Sponsor 's Safety Management Oversight Team ( SMOT ) order ass whether proceed next ascend dose level appropriate . The result communicate IDMC review . A formal IDMC review propose follow completion Cohort II ( toddler ) safety review , prior enrollment Cohorts III , IV , V ( infant ) . The study scheme summarize Figure 1 , detail safety review describe periodic safety data review ( SDR ) section . Electronic data capture ( EDC ) use collection data generate study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Healthy volunteer Acute chronic condition would interfere ability complete observation period Allergy egg vaccine component Receipt antibiotic Receipt immune modulate blood product Receipt pneumococcal vaccine concomitant participation vaccine drug trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>pneumococcal</keyword>
	<keyword>protein</keyword>
	<keyword>vaccine</keyword>
</DOC>